Biosimilars Market to Reach USD 185.2 Billion by 2035

Global biosimilars market is witnessing robust growth as healthcare systems increasingly adopt cost-effective biologic alternatives to improve patient access while reducing treatment expenses. According to recent market analysis, the global biosimilars market was valued at USD 38.7 billion in 2025 and is projected to reach USD 185.2 billion by 2035, expanding at a CAGR of 16.6% during the forecast period.

Browse more details about this report @ https://www.gminsights.com/industry-analysis/biosimilars-market

The market is benefiting from the growing prevalence of chronic diseases such as cancer, autoimmune disorders, diabetes, and blood-related conditions that require long-term biologic therapies. Biosimilars offer comparable safety, efficacy, and quality to reference biologics while significantly lowering treatment costs, making them an increasingly attractive option for healthcare providers, payers, and patients.

Rising awareness among physicians, supportive reimbursement policies, increasing regulatory approvals, and expanding acceptance across multiple therapeutic areas continue to strengthen market growth. Patent expirations of several blockbuster biologic drugs are also creating significant opportunities for biosimilar manufacturers worldwide.

Among product categories, recombinant glycosylated proteins generated USD 26.2 billion in revenue in 2025. The segment continues to expand due to increasing demand for advanced biologic therapies for chronic and life-threatening diseases. Advances in recombinant DNA technology and growing investments in biologics manufacturing are further supporting segment growth.

Based on application, the hematology segment accounted for 29.8% of the global market in 2025. Rising incidence of blood disorders, greater physician confidence in biosimilar safety and effectiveness, and increasing demand for affordable treatment options are driving wider adoption in hematology care.

Regionally, North America held 29.9% of the global biosimilars market in 2025 and is anticipated to grow at a 16.5% CAGR through 2035. Strong regulatory frameworks, increasing healthcare expenditure, favorable reimbursement policies, and continued patent expirations of major biologic products are accelerating biosimilar adoption across the region.

Leading companies operating in the global biosimilars market include Biocon, Sandoz, Bio-Thera Solutions, Pfizer, Dr. Reddy's Laboratories, Amgen, Teva Pharmaceuticals, Fresenius Kabi, Coherus Biosciences, Apobiologix, Biocad, Intas Pharma, Celltrion, Zydus Cadila, and Samsung Bioepis. These companies are expanding their market presence through product innovation, strategic collaborations, licensing agreements, manufacturing capacity expansion, and investments in advanced biologics production technologies.
As healthcare systems worldwide continue to prioritize affordable access to advanced biologic therapies, biosimilars are expected to play an increasingly important role in improving treatment accessibility and supporting sustainable healthcare spending over the coming decade.

Global Market Insights Inc. 4 North Main Street, Selbyville, Delaware 19975 USA
Toll free : +1-888-689-0688
USA : +1-302-846-7766
APAC : +65-3129-7718
Email: sales@gminsights.com

Global Market Insights Inc. (GMI) is a leading independent market research and consulting firm providing strategic business intelligence to mid-market companies, enterprises, and institutional investors. We deliver trusted market research and competitive analysis, helping organizations make informed decisions without the expense of traditional Big-4 consulting firms.

As an experienced market research firm, we help businesses navigate complex markets and opportunities with comprehensive intelligence for key decisions-like entering new markets, innovating products, or targeting niches. Our analysts provide customized research, benchmarking, and strategic insights to drive measurable growth.

This release was published on openPR.